Completed

DNCB Impact on Epidermal Langerhans Cells in AIDS/ARC Patients

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This study aims to investigate the impact of DNCB on epidermal Langerhans cells in patients diagnosed with AIDS or ARC.

What is being tested

Dinitrochlorobenzene

Drug
Who is being recruted

Blood-Borne Infections+14

+ Urogenital Diseases

+ Genital Diseases

From 18 to 55 Years
+10 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
See protocol details

Summary

Principal SponsorUniversity of California, San Francisco
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

This study focuses on AIDS and AIDS Related Complex (ARC) patients. It aims to understand the impact of a potent contact allergen called Dinitrochlorobenzene (DNCB) on specific skin cells known as epidermal Langerhans cells. These cells play a crucial role in the immune system. The study hopes to gain insights into how these cells respond to DNCB, which could potentially lead to improved treatments for AIDS and ARC patients.

NCT00002031
Principal SponsorUniversity of California, San Francisco
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 55 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesCommunicable DiseasesImmunologic Deficiency SyndromesImmune System DiseasesInfectionsRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSlow Virus DiseasesVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsAcquired Immunodeficiency SyndromeAIDS-Related ComplexHIV Infections

Criteria

2 inclusion criteria required to participate
Provide informed consent.
Stage III or IV HIV infection.
8 exclusion criteria prevent from participating
Radiation.
Allergy to lidocaine.
Prior DNCB therapy.
Kaposi's sarcoma lesions in the proposed treatment sites.
Show More Criteria

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

San Francisco AIDS Clinic / San Francisco Gen Hosp

San Francisco, United StatesOpen San Francisco AIDS Clinic / San Francisco Gen Hosp in Google Maps
CompletedOne Study Center